Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 3821 Records) |
| Query Trace: Lung Neoplasms and EGFR[original query] |
|---|
| Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer patients with epidermal growth factor receptor 21L858R mutation: A multicenter, case-series study in China. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2024 9 36 (4): 398-409. Shouzheng Wang, Jiayu Liu, Yan Wang, Ying Hu, Ziling Liu, Yu Yao, Li Liang, Yutao Liu, Lin Wang, Junling Li, Puyuan Xi |
| Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series. OncoTargets and therapy 2024 9 17 717-726. Kaoruko Shimbu, Kakeru Hisakane, Naohiro Kadoma, Shunichi Nishima, Kenichiro Atsumi, Masahiro Seike, Takashi Hiro |
| Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521. JCO global oncology 2024 9 10 e2400125. Bin-Chi Liao, Nai-Jung Chiang, Gee-Chen Chang, Wu-Chou Su, Yung-Hung Luo, Inn-Wen Chong, Tsung-Ying Yang, Chun-Liang Lai, Te-Chun Hsia, Ching-Liang Ho, Kang-Yun Lee, Chin-Fu Hsiao, Fan-Chen Ku, Wei-Tse Fang, James Chih-Hsin Ya |
| Exploring Genetic Variants and Platinum Chemotherapy Response in Indonesian Non-Small Cell Lung Cancer Patients: Insights from ERCC2 rs13181. OncoTargets and therapy 2024 9 17 767-776. Nadiya Nurul Afifah, Lanny Indah Permatasari, Ajeng Diantini, Ruri Intania, Indra Wijaya, Hideru Obinata, Melisa Intan Barlia |
| Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024 9 . Ping-Chih Hsu, John Wen-Cheng Chang, Li-Chung Chiu, Cheng-Ta Yang, Scott Chih-Hsi Kuo, Yueh-Fu Fang, Chiao-En |
| Negative-predictive value of SUVmax for Ascertaining the efficacy of osimertinib in EGFR mutation-positive non-small cell lung cancer. Respiratory investigation 2024 9 62 (6): 1072-1078. Moriyasu Anai, Hiroki Inoue, Koichi Saruwatari, Seitaro Oda, Shinya Shiraishi, Kimitaka Akaike, Kosuke Imamura, Takayuki Jodai, Shinya Sakata, Shinji Iyama, Yusuke Tomita, Hidenori Ichiyasu, Takuro Sakaga |
| Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples. Journal of clinical laboratory analysis 2024 9 e25099. Yi Sun, Xu Zhang, Xinhua Yang, Jiangjun |
| Clinical and Genetic Characteristics of Early-onset Lung Adenocarcinoma in a Large Chinese Cohort. The Annals of thoracic surgery 2024 9 . Shouzhi Xie, Qikang Hu, Zeyu Wu, Bin Wang, Yu He, Qi Huang, Zhe Zhang, Zhi Yang, Shengrong Wu, Weiyu Yang, Xinhang Hu, Xuyang Yi, Hao He, Cheng Wang, Fenglei Yu, Muyun Pe |
| Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01. Targeted oncology 2024 9 . Makoto Hibino, Yoshinori Imamura, Rai Shimoyama, Tomoya Fukui, Ryuta Fukai, Akihiko Iwase, Yukihiro Tamura, Yusuke Chihara, Takafumi Okabe, Kiyoaki Uryu, Tadahisa Okuda, Masataka Taguri, Hironobu Mina |
| Tumor markers in non-small cell lung cancer spine metastasis: an assessment of prognosis and overall survival. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 2024 9 . Brian Foresi, Aakash Shah, Seth Meade, Ajit Krishnan |
| Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma. Experimental & molecular medicine 2024 9 . Hyondeog Kim, Wonyeop Lee, Youngwook Kim, Sang-Jin Lee, Wonyoung Choi, Geon Kook Lee, Seung-Jin Park, Shinyeong Ju, Seon-Young Kim, Cheolju Lee, Ji-Youn H |
| Outcomes with non-small cell lung cancer and brain-only metastasis. Heliyon 2024 9 10 (17): e37082. Sabine Schmid, Miguel Garcia, Luna Zhan, Sierra Cheng, Khaleeq Khan, Maisha Chowdhury, Amir Sabouhanian, Joshua Herman, Preet Walia, Evan Strom, M Catherine Brown, Devalben Patel, Wei Xu, Frances A Shepherd, Adrian G Sacher, Natasha B Leighl, Penelope A Bradbury, Geoffrey Liu, David Shul |
| Assessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for EGFR Mutation Detection in NSCL. Iranian biomedical journal 2024 9 28 (4): 208-15. Mohammad Mehdi Jahani, Parisa Mashayekhi, Mir Davood Omrani, Adnan Khosravi, Dehghanifard Ali, Sanam Azad Manjiri, Mahyar Zahraei, Maryam Mabani, Sharareh Seifi, Babak Salimi, Parsa Rosta |
| Molecular Testing for EGFR Mutation in Moroccan NSCLC Patients: CHU Hassan II-Fez Experience. International journal of surgical pathology 2024 9 10668969241268379. Sara Boukansa, Ismail Mouhrach, Fatima El Agy, Sanaa Gamrani, Laila Bouguenouch, Mounia Serraj, Bouchra Amara, Yassine Ouadnouni, Mohamed Smahi, Badreeddine Alami, Nawfel Mellas, Zineb Benbrahim, Hinde El Fate |
| Immunotherapy plus chemotherapy for patients with EGFR-mutated non-squamous cell lung cancer for disease progression after EGFR tyrosine-kinase inhibitor: A meta-analysis of randomized controlled trials. Oncology 2024 9 1-26. Ahmed A Refae, Rafat I Abu Shakra, Ezzeldin M Ibrah |
| The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer. OncoTargets and therapy 2024 9 17 755-763. YuXuan Zhang, Yuhong Shen, Jiayuan Wu, Jun Zhang, Chenxi Cao, Juanfen Mo, Yi B |
| It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC. Exploration of targeted anti-tumor therapy 2024 9 5 (4): 826-840. Ken Akao, Yuko Oya, Takaya Sato, Aki Ikeda, Tomoya Horiguchi, Yasuhiro Goto, Naozumi Hashimoto, Masashi Kondo, Kazuyoshi Imaizu |
| Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space. Translational lung cancer research 2024 9 13 (8): 1862-1876. Kuan Xu, Yilv Lv, Tangbing Chen, Yuchen Han, Hanqing Huang, Hong Yu, Bo |
| Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment. American journal of clinical oncology 2024 9 . Zaheer Qureshi, Faryal Altaf, Abdur Jamil, Rimsha Siddiq |
| Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile. Chinese clinical oncology 2024 9 . Jens Benn Sørensen, Eric Santoni-Rugiu, Edyta Maria Urbans |
| Comparative genomic and immunopathologic analysis of lung adenocarcinomas with and without cytology-proven malignant pleural effusions. Cancer cytopathology 2024 8 . Cristiana M Pineda, Adnan Majid, Daniel B Costa, Paul A VanderLa |
| Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen. Lung cancer (Amsterdam, Netherlands) 2024 8 195 107933. Ke-Jun Liu, Hong-Rui Li, Quan-Quan Tan, Tao Jiang, Kai-Cheng Peng, Hua-Jun Chen, Qing Zhou, Xu-Chao Zhang, Zheng Zheng, Shi-Yuan Chen, Xue Zheng, Hong-Bo Zheng, Bei-Bei Mao, Long-Long Gong, Xian-Wen Chen, Wendy Wu, Yi-Long Wu, Jun Jia, Jin-Ji Ya |
| A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future oncology (London, England) 2024 8 19 (33): 2213-2225. Alexander Spira, Nicolas Girard, Matthew Krebs, Keunchil Park, Catherine Shu, Lindsay Dougherty, Byoung Chul C |
| Analysis of the effect of baseline detection and early clearance of ct-DNA, on survival outcomes among patients with advanced EGFR-mutant non-small cell lung cancer. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2024 8 38 (1): 40-49. A Joel, R Abarna, R T Chacko, A Singh, J T Georgy, A O John, D B Thumaty, S Balukrishna, R Isiah, S Paavamani, T A Kodiatte, S Rima, G Rebekah, R P |
| Combination Therapy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel for Metastatic Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Resistance and EGFR Mutations. Cureus 2024 8 16 (8): e67307. Hironori Kobayashi, Ayumu Otsuki, Sadakatsu Ikeda, Kei Nakashima, Yu Oya |
| Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis. ESMO open 2024 8 9 (9): 103660. Z Piotrowska, B Y Yeap, J F Gain |
| Investigation of the Efficacy of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor in Patients With EGFR Exon 21 L858R Point Mutation-Positive Non-small Cell Lung Cancer. Cureus 2024 8 16 (7): e64811. Yutaka Takahara, Ryudai Abe, Sumito Nagae, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Masafumi Nojiri, Masaharu Iguc |
| Exposure-response modelling of osimertinib in patients with non-small cell lung cancer. British journal of clinical pharmacology 2024 8 . Martin Johnson, Yu-Wei Lin, Henning Schmidt, Mikael Sunnaker, Eline Van Maanen, Xiangning Huang, Yuri Rukazenkov, Helen Tomkinson, Karthick Vishwanath |
| [Chinese Expert Consensus on the Standardized Diagnosis and Treatment of ?Non?small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2024 8 27 (7): 485-494. Authors are not available |
| RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer. Clinical lung cancer 2024 8 . Amanda Reyes, Michelle Afkhami, Erminia Massarelli, Jeremy Fricke, Isa Mambetsariev, Xiaochen Li, Giovanny Velasquez, Ravi Salg |
- Page last reviewed:Feb 1, 2024
- Content source: